查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1560207

伴同性动物疫苗市场报告：2030 年趋势、预测与竞争分析

Companion Animal Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

伴同性动物疫苗趋势和预测

预计到 2030 年，全球伴同性动物疫苗市场将达到 48 亿美元，2024 年至 2030 年复合年增长率为 6.3%。该市场的主要驱动因素是人们对宠物疫苗接种重要性的认识不断提高、通用感染疾病病例不断增加以及世界各地对养宠物的兴趣日益浓厚。全球伴同性动物疫苗市场的未来看起来充满希望，医院/诊所和研究实验室市场存在机会。

Lucintel 预测，由于饲主对疫苗接种以保护宠物免受严重疾病的重要性的认识不断提高，狗仍将是最大的细分市场。

在这个市场中，医院和诊所预计将在预测期内实现最高成长。由于宠物拥有量较高以及该地区人们对宠物疫苗接种重要性的认识不断增强，北美仍将是最大的地区。

伴同性动物疫苗市场的新趋势

由于技术进步、消费者偏好的变化和新的法规环境，伴同性动物疫苗市场正在快速发展。未来的趋势正在塑造这个市场，推动疫苗开发、分销和管理方面的创新。

  • 个人化疫苗：基因分析可以开发出适合个别宠物需求的个人化疫苗，而这个概念正变得越来越流行。这种趋势在日本和美国等国家尤其明显，这些国家的宠物饲主正在为他们的动物寻求量身定制的医疗保健解决方案。这些疫苗非常有效且副作用最小，使其成为首选。
  • 基于 DNA 和 RNA 的疫苗：DNA 和 RNA 作为疫苗的使用正在增加，因为它们可以针对多种疾病提供快速保护。此类疫苗在对抗新出现的感染疾病特别有效。许多公司正在美国和欧洲市场开发这些尖端疫苗。
  • 越来越关注通用感染疾病的预防：随着通用感染疾病变得越来越普遍，人们越来越关注疫苗，它不仅可以保护宠物免受感染疾病，还可以降低将其传播给人类的风险。在德国等国家，这种趋势正在加剧，动物健康是公共卫生的重要组成部分。此类疫苗将在综合健康策略中发挥核心作用。
  • 扩大疫苗的取得范围：全球改善疫苗取得的势头不断增强，特别是在印度和中国等新兴国家。这将透过提高疫苗接种率以及透过产业和政府之间的合作使疫苗变得负担得起并广泛提供来改善整体动物健康结果。
  • 生物技术的整合：将先进的生物技术融入疫苗开发中正在显着改变市场。科学家开始使用 CRISPR 和合成生物学等技术来创造更安全、更好的疫苗。这一趋势预计将导致新一代疫苗具有更高的功效、在设计过程中满足安全需求以及快速且有效率的生产。

伴同性动物疫苗市场的未来正受到这些向更有效率、个人化和可及的疫苗发展的趋势的推动。这些进展将重塑疫苗的配製、传播和使用方式，从而改善全球伴同性动物的健康前景。

伴同性动物疫苗市场的最新趋势

几项重大发展推动了伴同性动物疫苗市场的成长和演变。这些改进显示对新型高效疫苗的需求不断增加，以及最大限度地提高全球可及性和有效性的努力。

  • 创新的 DNA 疫苗：DNA 疫苗的最新进展正在以更少的剂量实现更大的覆盖范围。这些疫苗旨在对抗多种疾病，为宠物动物提供更有效、更有针对性的疫苗接种选择。
  • 扩大全球生产：疫苗製造商正在投资建造新的生产工厂，以增加疫苗供应，特别是在中国和印度等开发中国家。这种扩张对于满足世界各地对疫苗不断增长的需求并确保按时供应至关重要。
  • 预防通用感染疾病的联合计画：兽医研究中心和製药公司之间的联合计画正在开发针对通用传染病的疫苗。这些疫苗可以保护宠物和人类，反映出人们对公共卫生方法的日益关注。
  • 低成本免疫计划：一些公司正在推出廉价疫苗以提高免疫率，特别是在开发中国家。这些市场倡议得到了公共卫生计划的支持，其主要目标是让公众意识到宠物疫苗接种的重要性并减少该市场的健康风险。
  • 个人化疫苗的製造：在日本和其他已开发市场，个人疫苗已成为一种偏好，对品种和个人疫苗的研究正在取得进展。这是因为它更有效并且被饲主所接受，因为它满足了宠物的特定医疗保健需求。

这些全球趋势透过培育创新理念、获得全球关注以及提高疫苗的整体效率和可用性，正在塑造伴同性动物疫苗市场。展望未来，这将对改善伴同性动物医疗保健服务的未来潜在需求产生影响。

伴同性动物疫苗市场的策略性成长机会

伴同性动物疫苗市场提供了几个策略性成长机会，特别是在某些关键应用领域。这些源自于疫苗技术的进步、宠物拥有量的增加以及对全球动物健康日益增长的兴趣。

  • 疾病特异性疫苗：针对特定地区流行的特定疾病的疫苗的开发代表了一个主要的成长机会。透过专注于生产高流行性疾病疫苗，公司可以提供自订的解决方案，成功应对当地的健康挑战。
  • 生物技术主导的疫苗开发：将 CRISPR 和合成生物学等生物技术纳入疫苗开发中，正在开闢生产更有效、更安全疫苗的新方法。在这个领域，公司有潜力透过提供尖端疫苗来满足宠物饲主不断变化的需求，从而进行创新并获得市场占有率。
  • 新兴市场的扩张：宠物饲主数量的不断增加以及对优质兽医服务的需求不断增长，使得印度和中国等新兴市场成为有吸引力的投资目的地。在这些市场建立本地生产设施和分销网络的公司拥有很高的成长机会。
  • 线上和直接面向消费者的销售：线上平台和直接面向消费者的管道的兴起正在为疫苗分销创造新的机会。利用电子商务和数位行销的公司可以为更多人提供疫苗，特别是在兽医服务有限的地区。
  • 预防性医疗保健计划：包括疫苗、定期检查和其他基本服务在内的预防性医疗保健计划正在增加。这些套餐使宠物饲主更容易接受疫苗接种等常规医疗护理，最终改善所有动物的健康。

技术创新、市场扩张和疫苗供应等策略性成长机会已经改变了伴同性动物疫苗市场。透过利用这些机会，公司可以在这个不断变化的行业中获得优势。

伴同性动物疫苗市场驱动因素与挑战

影响伴同性动物疫苗市场的关键驱动因素包括技术创新、宠物拥有量的增加以及动物健康意识的提高。但障碍也存在，包括监管合规障碍、高昂的研发成本以及一些饲主对疫苗的犹豫。这些因素共同影响市场的状况。

推动伴同性动物疫苗市场的因素包括：

1.技术创新：生物技术的进步，例如基于DNA和RNA的疫苗，正在导致更有效的标靶疫苗的生产，从而改善宠物的健康并扩大马苏的市场规模。

2. 增加宠物拥有量：宠物拥有量的增加，特别是在都市区，增加了对伴同性动物疫苗的需求，以确保宠物的医疗保健。

3.提高动物健康意识：疫苗接种率很高，特别是在医学素养率较高的新兴市场，因为人们对疫苗接种预防疾病的知识很丰富。

4. 政府支持和监管：政府支持政策和简化的监管流程正在促进新兴市场的疫苗开发和分配。

5.通用感染疾病的增加：通用感染疾病的日益流行增加了对同时针对动物和人类的疫苗的需求。

伴同性动物疫苗市场面临的挑战包括：

1. 监管障碍：这项挑战可能会限制疫苗公司，因为应对复杂且地区不同的法规环境可能会延迟疫苗核准和市场准入。

2.研发成本高：研发成本高：研发成本高，特别是创新疫苗，会阻碍市场进入并抑制中小企业的竞争。

3. 疫苗犹豫不决：安全问题、副作用和错误讯息阻碍了一些饲主为宠物接种疫苗，从而阻碍了市场成长。

这些驱动因素和挑战决定了伴同性动物疫苗市场将如何发展。儘管存在许多与技术进步和需求增加相关的机会，但克服监管的财务障碍将是该行业持续成长的关键。

伴同性动物疫苗按市场

该研究包括按产品类型、物种类型、最终用途和地区分類的伴同性动物疫苗的全球预测。

国家伴同性动物疫苗市场前景

由于宠物数量的增加、疫苗技术的创新以及动物健康意识的提高，全球伴同性动物疫苗市场正在经历一些改善。此外，政府倡议以及对可保护宠物免受各种疾病的安全有效疫苗的需求不断增加，也促进了该市场的成长。以下的摘要重点介绍了美国、中国、德国、印度和日本的最新发展。

  • 美国：在美国，基于 DNA 的伴同性动物疫苗的开发正在取得重大进展。这些公司正在投资研究，开发以更少剂量提供广泛保护的疫苗。我们也致力于改善我们的分销网络，以确保在全国范围内及时供货。
  • 中国 在中国，中国政府正在加强对本土疫苗生产的支持。最近的发展包括与全球公司建立合作伙伴关係以及建立新的製造工厂，以提高未来疫苗的品质和可用性。也重点关注扩大都市区伴同性动物的疫苗接种覆盖范围。
  • 德国 德国正致力于开发针对新出现的通用感染疾病的疫苗。兽医研究机构和製药公司最近的合作旨在开发不仅能保护动物，还能降低疾病传播给人类的风险的疫苗。
  • 印度都市区宠物拥有量的增加是印度伴同性动物疫苗市场成长的主要驱动力。最近的努力包括推出负担得起的疫苗选择和进行宣传宣传活动以提高疫苗接种率。政府也正在简化监管核准，以更快提供新疫苗。
  • 日本 在日本，有一种趋势是为伴同性动物提供个人化疫苗，并专注于特定品种的健康问题。在这方面，最新的发展涉及先进的生物技术，可以根据个别宠物的基因谱开发客製化的疫苗，确保更好的疾病预防。

常问问题

Q.1伴同性动物疫苗的市场规模有多大？

A1. 到 2030 年，全球伴同性动物疫苗市场预计将达到 48 亿美元。

Q.2伴同性动物疫苗市场的成长预测如何？

A2. 2024年至2030年，全球伴同性动物疫苗市场预计将以6.3%的复合年增长率成长。

Q.3 影响伴同性动物疫苗市场成长的关键驱动因素有哪些？

A3. 该市场的主要驱动因素是人们对宠物疫苗接种重要性的认识不断提高、通用感染疾病病例不断增加以及世界各地对养宠物的兴趣日益浓厚。

Q4.市场的主要细分市场是：

A4.伴同性动物疫苗市场的前景在医院/诊所市场和研究所市场似乎很有前景。

Q5.市场的主要企业是：

A5.伴同性动物疫苗主要企业如下：

  • Elanco
  • Boehringer Ingelheim International
  • Intervet
  • Zoetis Services
  • Bioveta
  • Sanofi
  • Bayer
  • Heska
  • Virbac
  • Hester Biosciences

Q6.伴同性动物疫苗未来哪个区隔市场将成为最大？

A6.Lucintel 预测，由于狗饲主对疫苗接种以保护宠物免受严重疾病的重要性的认识不断提高，狗将继续成为最大的细分市场。

Q7. 未来五年哪个地区预计将成为伴同性动物疫苗市场最大的地区？

A7. 由于宠物拥有率高以及该地区人口对宠物疫苗接种重要性的认识不断提高，北美将继续成为最大的地区。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球伴同性动物疫苗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球宠物动物疫苗市场趋势（2018-2023）与预测（2024-2030）
  • 按产品类型分類的全球伴同性动物疫苗市场
    • 腐烂活着
    • 共轭
    • 惰性
    • 次单元
    • 类毒素
    • DNA
    • 重组
  • 全球伴同性动物疫苗市场、类型
    • 狗
    • 鸟类
    • 猫科动物
    • 马
  • 全球伴同性动物疫苗市场（依最终用途）
    • 医院/诊所
    • 研究所
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 全球伴同性动物疫苗市场区域分布
  • 北美伴同性动物疫苗市场
  • 欧洲伴同性动物疫苗市场
  • 亚太地区伴同性动物疫苗市场
  • 其他区域伴同性动物疫苗市场

第五章 竞争分析

  • 产品系列分析
  • 业务整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 按产品类型分類的全球伴同性动物疫苗市场成长机会
    • 全球伴同性动物疫苗市场按类型分類的成长机会
    • 按最终用途分類的全球伴同性动物疫苗市场的成长机会
    • 全球伴同性动物疫苗市场成长机会（按地区）
  • 全球伴同性动物疫苗市场的新趋势
  • 战略分析
    • 新产品开发
    • 全球伴同性动物疫苗市场产能扩张
    • 全球伴同性动物疫苗市场的併购和合资企业
    • 认证和许可

第七章主要企业概况

  • Elanco
  • Boehringer Ingelheim International
    • Intervet
  • Zoetis Services
  • Bioveta
  • Sanofi
  • Bayer
  • Heska
  • Virbac
  • Hester Biosciences
简介目录

Companion Animal Vaccine Trends and Forecast

The future of the global companion animal vaccine market looks promising with opportunities in the hospital & clinic and research institute markets. The global companion animal vaccine market is expected to reach an estimated $4.8 billion by 2030 with a CAGR of 6.3% from 2024 to 2030. The major drivers for this market are rising awareness about importance of pet vaccination, growing cases of zoonotic diseases, and increasing interest for pet ownership in the world.

Lucintel forecasts that canines will remain the largest segment due to increasing awareness of the importance of this vaccination among dog owners for protecting their pets from serious diseases.

Within this market, hospital & clinics are expected to witness the highest growth over the forecast period. North America will remain the largest region due to high pet ownership rates and increasing awareness of the importance of pet vaccination among the population in the region.

Emerging Trends in the Companion Animal Vaccine Market

The market for Companion Animal Vaccines is evolving at a rapid pace due to technological advances, changing consumer preferences, and new regulatory environments. Future trends are shaping up this market which prompt innovations in vaccine development, distribution, and administration.

  • Personalized Vaccines: Genetic profiling has enabled the development of personalized vaccines tailored to individual pets' requirements which is making this concept increasingly popular. This trend is particularly pronounced in countries like Japan and the USA where pet owners seek bespoke healthcare solutions for their animals. These vaccines offer increased efficacy with minimum side effects hence becoming the preferred choice.
  • DNA and RNA-Based Vaccines: The use of DNA and RNA as vaccines is increasing because they offer quick protection against a broad range of diseases. These kinds of vaccines are especially beneficial in fighting emerging infectious diseases. Many companies are developing these cutting-edge vaccines in the US and European markets.
  • Increasing Focus on Zoonotic Disease Prevention: The emphasis on vaccines, which are not only designed to protect pets from infectious diseases but also reduce the risk of transmitting them to humans, is rising as zoonoses become more prevalent. In places like Germany where animal health is an integral part of public health, this trend is picking up. These vaccines would also be central to integrated health strategies.
  • Expanding Vaccine Accessibility: There is a growing momentum towards improving vaccine access globally, particularly in emerging economies such as India and China. This has increased vaccination rates and improved overall animal health outcomes by making vaccines affordable and widely available through collaborations between businesses and governments.
  • Biotechnology Integration: Incorporating advanced biotechnology into vaccine development is transforming the market. Scientists have started using technologies such as CRISPR and synthetic biology that create better yet safer vaccines. New generations of vaccines with greater effectiveness, safety needs addressed during their design process, and quick efficient production are expected to result from this trend.

The future of the companion animal vaccine market is being pushed by these trends towards more efficient, individualized, and accessible vaccines. These developments will reshape how vaccines are formulated, spread out, and put into use as a result of improving companion animals' health outlooks globally.

Recent Developments in the Companion Animal Vaccine Market

The growth and evolution of the companion animal vaccine market have been driven by several important developments. These improvements indicate an increasing need for new and efficient vaccines as well as the attempts to maximize global access and efficacy.

  • Innovative DNA-based Vaccines: Recent advances in DNA-based vaccines are making great strides toward broader coverages with reduced doses. Designed to fight various diseases, these vaccines offer more effective and targeted immunization options for pet animals.
  • Global Manufacturing Expansion: Vaccine producers are investing in new production plants, especially in developing countries including China and India that help increase the supply of vaccines. The expansion is crucial in addressing the increasing demand for vaccines worldwide as well as ensuring their availability on time.
  • Collaborations for Zoonotic Disease Prevention: Joint ventures between veterinary research centers and pharmaceutical firms have resulted in the development of vaccines against zoonotic diseases. These vaccines serve to protect both pets and humans, which reflects a growing focus on connected public health approaches.
  • Low-Cost Immunization Plan: Some corporations are introducing cheap vaccines to improve immunization rates, especially in the developing world. These market initiatives are backed up by public health programs whose main objective is to sensitize the public to the importance of pet vaccination hence reducing this market's health risks.
  • Individualised Vaccine Production: In Japan and other highly-developed markets personal vaccines have become preferable, leading to research on breed or individually tailored vaccine versions. This is because they are more effective and meet the distinct healthcare needs of pets, thus being embraced by pet owners.

These trends combine to shape the companion animal vaccine market by fostering innovative ideas, extending prominence globally, and increasing vaccines' overall efficiency along with availability. Henceforth, this will influence what will occur concretely in terms of future potential demand for companion animal healthcare services as far as its improvement is concerned.

Strategic Growth Opportunities for Companion Animal Vaccine Market

Several strategic growth opportunities are available in the companion animal vaccine market, especially in certain key application segments. These arise from advancements in vaccine technology, increased pet ownership, and a growing global animal health focus.

  • Disease-Specific Vaccines: The development of vaccines targeting specific diseases characterized by their prevalence in particular geographical areas represents a significant opportunity for growth. Companies can concentrate on making vaccines for diseases that are hyper-endemic, thereby providing custom-made solutions that successfully address local health challenges.
  • Biotechnology-Driven Vaccine Development: The incorporation of biotechnology into vaccine development such as CRISPR and synthetic biology is opening up new ways to produce more effective and safer vaccines. In this area, companies have the potential to innovate and gain market share by providing cutting-edge vaccines that meet the changing demands of pet owners.
  • Expansion in Emerging Markets: Growing numbers of pets' owners coupled with rising demand for quality veterinary services make emerging markets like India and China attractive for investment. Those companies that establish local production facilities and distribution networks within these markets will have access to the high-growth opportunities they offer.
  • Online and Direct-to-Consumer Sales: The rise of online platforms and direct-to-consumer sales channels is creating new opportunities for vaccine distribution. Companies that leverage e-commerce and digital marketing can reach a wider audience, especially in places where veterinary services are limited.
  • Preventive Healthcare Packages: Preventive healthcare package options that include vaccines, routine check-ups, and other basic services are on the rise. These packages make it easier for pet owners to get the medical care they need on a regular basis including vaccination among others which will eventually lead to better health for all animals.

Strategic growth opportunities like innovation, market expansion, accessibility of vaccines have changed the marketplace for Companion Animal Vaccines. Taking advantage of these opportunities will put businesses at an advantageous position in this changing industry.

Companion Animal Vaccine Market Driver and Challenges

Key drivers that shape the companion animal vaccine market include; Technological innovation, increased pet ownership, and an increase in awareness of animal health. However, there are also hurdles such as regulatory compliance barriers, high research and development costs, and some pet owners who show hesitance towards vaccines. Taken together, these elements affect what happens in the marketplace.

The factors responsible for driving the companion animal vaccine market include:

1. Technological Innovation: Biotechnology advances such as DNA and RNA-based vaccines have led to the production of more efficient targeted vaccines resulting in improved health outcomes for pets thereby expanding the market reach.

2. Increasing Pet Ownership: The higher incidence of pet ownership particularly in cities is driving up demand for companion animal vaccines so that they can ensure their pets' well-being is taken care of.

3. Growing Awareness of Animal Health: Informed people have a better vaccination rate due to their knowledge about diseases prevention by vaccination especially among developed markets where healthcare literacy levels are high among other reasons.

4. Government Support and Regulations: In emerging markets, vaccines are being developed and distributed with the help of supportive government policies and simplified regulatory processes.

5. Rise of Zoonotic Diseases: The increasing prevalence of zoonotic diseases has resulted in a demand for vaccines that address both animals and humans simultaneously.

Challenges in the companion animal vaccine market are:

1. Regulatory Hurdles: Navigating complex and varying regulatory environments across different regions can delay vaccine approvals and market entry; this challenge may limit vaccine companies.

2. High R&D Costs: High R&D costs, especially for innovative vaccines, can hinder entry into a market and curtail competition from smaller firms.

3. Vaccine Hesitancy: Safety concerns, side effects, or false information prevent some pet owners from vaccinating their pets thus hindering market growth.

These drivers along with the challenges delineate how the companion animal vaccine market is evolving. There are numerous opportunities associated with technology advancements as well as increasing demand but overcoming economic barriers to regulation will be key if this industry is to continue experiencing growth.

List of Companion Animal Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies companion animal vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the companion animal vaccine companies profiled in this report include-

  • Elanco
  • Boehringer Ingelheim International
  • Intervet
  • Zoetis Services
  • Bioveta
  • Sanofi
  • Bayer
  • Heska
  • Virbac
  • Hester Biosciences

Companion Animal Vaccine by Segment

The study includes a forecast for the global companion animal vaccine by product type, species type, end use, and region.

Companion Animal Vaccine Market by Product Type [Analysis by Value from 2018 to 2030]:

  • Attenuated Live
  • Conjugate
  • Inactivated
  • Subunit
  • Toxoid
  • DNA
  • Recombinant

Companion Animal Vaccine Market by Species Type [Analysis by Value from 2018 to 2030]:

  • Canine
  • Avian
  • Feline
  • Equine

Companion Animal Vaccine Market by End Use [Analysis by Value from 2018 to 2030]:

  • Hospitals & Clinics
  • Research Institutes
  • Others

Companion Animal Vaccine Market by Region [Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Companion Animal Vaccine Market

The companion animal vaccine market has seen several improvements across the world due to increased pet ownership, innovation in vaccine technology, and growing consciousness of animal health. Moreover, this market's growth is augmented by government initiatives and a rise in demand for safe and efficient vaccines that can protect pets from different ailments. The summary below highlights recent trends within the United States, China, Germany, India, and Japan.

  • United States: In America, there have been significant strides in developing DNA-based vaccines for pets. These companies are investing in research that aims at creating vaccines that offer wider protection with a lower number of doses. Moreover, efforts have been made to improve the distribution network to make them available on time across the country.
  • China: In China, there has been greater support from the Chinese government toward their local vaccine production. Some of these recent developments include the establishment of new manufacturing plants together with partnerships with worldwide companies aimed at improving the quality as well as accessibility of vaccines in the future. There is also a focus on expanding vaccination coverage to companion animals living in urban areas.
  • Germany: Germany has concentrated on developing vaccines against emerging zoonotic infections. Some recent collaborations between veterinary research institutes and pharmaceutical companies aim to create vaccines that not only protect animals but also reduce the risk of disease transmission to humans.
  • India: The rise in urban pet ownership has been the key driver for growth in India's companion animal vaccine market. Some recent initiatives include affordable vaccine options being launched and awareness campaigns executed to increase vaccination rates. The government has also streamlined regulatory approvals to make new vaccines available more quickly.
  • Japan: There is a trend towards personalized vaccines for companion animals, with an emphasis on breed-specific health issues in Japan. In this regard, some of the latest developments involve advanced biotechnology that allows for the development of custom-made immunizations based on genetic profiles of individual pets and ensures better disease prevention.

Features of the Global Companion Animal Vaccine Market

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Companion animal vaccine market size by product type, species type, end use, and region in terms of value ($B).

Regional Analysis: Companion animal vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product types, species types, end uses, and regions for the companion animal vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the companion animal vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the companion animal vaccine market size?

Answer: The global companion animal vaccine market is expected to reach an estimated $4.8 billion by 2030.

Q.2 What is the growth forecast for the companion animal vaccine market?

Answer: The global companion animal vaccine market is expected to grow with a CAGR of 6.3% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the companion animal vaccine market?

Answer: The major drivers for this market are rising awareness about the importance of pet vaccination, growing cases of zoonotic diseases, and increasing interest for pet ownership in the world.

Q4. What are the major segments for companion animal vaccine market?

Answer: The future of the companion animal vaccine market looks promising with opportunities in the hospital & clinic and research institute markets.

Q5. Who are the key companion animal vaccine market companies?

Answer: Some of the key companion animal vaccine companies are as follows:

  • Elanco
  • Boehringer Ingelheim International
  • Intervet
  • Zoetis Services
  • Bioveta
  • Sanofi
  • Bayer
  • Heska
  • Virbac
  • Hester Biosciences

Q6. Which companion animal vaccine market segment will be the largest in the future?

Answer: Lucintel forecasts that canine will remain the largest segment due to increasing awareness of the importance of this vaccination among dog owners for protecting their pets from serious diseases.

Q7. In the companion animal vaccine market, which region is expected to be the largest in the next 5 years?

Answer: North America will remain the largest region due to high pet ownership rates and increasing awareness of the importance of pet vaccination among the population in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the companion animal vaccine market by product type (attenuated live, conjugate, inactivated, subunit, toxoid, DNA, and recombinant), species type (canine, avian, feline, and equine), end use (hospitals & clinics, research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
  • Market Report

Table of Contents

1. Executive Summary

2. Global Companion Animal Vaccine Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Companion Animal Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Companion Animal Vaccine Market by Product Type
    • 3.3.1: Attenuated Live
    • 3.3.2: Conjugate
    • 3.3.3: Inactivated
    • 3.3.4: Subunit
    • 3.3.5: Toxoid
    • 3.3.6: DNA
    • 3.3.7: Recombinant
  • 3.4: Global Companion Animal Vaccine Market by Species Type
    • 3.4.1: Canine
    • 3.4.2: Avian
    • 3.4.3: Feline
    • 3.4.4: Equine
  • 3.5: Global Companion Animal Vaccine Market by End Use
    • 3.5.1: Hospitals & Clinics
    • 3.5.2: Research Institutes
    • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Companion Animal Vaccine Market by Region
  • 4.2: North American Companion Animal Vaccine Market
    • 4.2.1: North American Companion Animal Vaccine Market by Species Type: Canine, Avian, Feline, and Equine
    • 4.2.2: North American Companion Animal Vaccine Market by End Use: Hospitals & Clinics, Research Institutes, and Others
  • 4.3: European Companion Animal Vaccine Market
    • 4.3.1: European Companion Animal Vaccine Market by Species Type: Canine, Avian, Feline, and Equine
    • 4.3.2: European Companion Animal Vaccine Market by End Use: Hospitals & Clinics, Research Institutes, and Others
  • 4.4: APAC Companion Animal Vaccine Market
    • 4.4.1: APAC Companion Animal Vaccine Market by Species Type: Canine, Avian, Feline, and Equine
    • 4.4.2: APAC Companion Animal Vaccine Market by End Use: Hospitals & Clinics, Research Institutes, and Others
  • 4.5: ROW Companion Animal Vaccine Market
    • 4.5.1: ROW Companion Animal Vaccine Market by Species Type: Canine, Avian, Feline, and Equine
    • 4.5.2: ROW Companion Animal Vaccine Market by End Use: Hospitals & Clinics, Research Institutes, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Companion Animal Vaccine Market by Product Type
    • 6.1.2: Growth Opportunities for the Global Companion Animal Vaccine Market by Species Type
    • 6.1.3: Growth Opportunities for the Global Companion Animal Vaccine Market by End Use
    • 6.1.4: Growth Opportunities for the Global Companion Animal Vaccine Market by Region
  • 6.2: Emerging Trends in the Global Companion Animal Vaccine Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Companion Animal Vaccine Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Companion Animal Vaccine Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Elanco
  • 7.2: Boehringer Ingelheim International
    • 7.1.1: Intervet
  • 7.4: Zoetis Services
  • 7.5: Bioveta
  • 7.6: Sanofi
  • 7.7: Bayer
  • 7.8: Heska
  • 7.9: Virbac
  • 7.10: Hester Biosciences